Ebola immunity: Gaining a winning position in lightning chess

Journal of Immunology

Volumn 201, Issue 3, 2018, Pages 833-842

  Ploquin, Aurélie ^a   Zhou, Yan ^a   Sullivan, Nancy J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; VIRUS ANTIBODY;

ANTIBODY RESPONSE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DISEASE MODEL; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INTERFERON PRODUCTION; LYMPHOCYTE ACTIVATION; MACROPHAGE; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; VIRAL CLEARANCE; VIRUS TRANSMISSION; ZAIRE EBOLAVIRUS; ANIMAL; EBOLAVIRUS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, VIRAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HOST-PATHOGEN INTERACTIONS; HUMANS;

EID: 85050739642     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1700827     Document Type: Review

References (154)

1. International-commission. 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull. World Health Organ. 56: 271-293.
2. Centers for Disease Control and Prevention. 2015. Outbreaks chronology: Ebola virus disease. Atlanta, GA: Centers for Disease Control and Prevention. http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html. Accessed: November 11, 2015.
3. Leroy, E. M., B. Kumulungui, X. Pourrut, P. Rouquet, A. Hassanin, P. Yaba, A. Délicat, J. T. Paweska, J. P. Gonzalez, and R. Swanepoel. 2005. Fruit bats as reservoirs of Ebola virus. Nature 438: 575-576.
4. Bausch, D. G., J. S. Towner, S. F. Dowell, F. Kaducu, M. Lukwiya, A. Sanchez, S. T. Nichol, T. G. Ksiazek, and P. E. Rollin. 2007. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J. Infect. Dis. 196(Suppl. 2): S142-S147.
5. Dowell, S. F., R. Mukunu, T. G. Ksiazek, A. S. Khan, P. E. Rollin, and C. J. Peters. 1999. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit. J. Infect. Dis. 179(Suppl. 1): S87-S91.
6. Mate, S. E., J. R. Kugelman, T. G. Nyenswah, J. T. Ladner, M. R. Wiley, T. Cordier-Lassalle, A. Christie, G. P. Schroth, S. M. Gross, G. J. Davies-Wayne, et al. 2015. Molecular evidence of sexual transmission of Ebola virus. N. Engl. J. Med. 373: 2448-2454.
7. Centers for Disease Control and Prevention. 2015. 2014 Ebola outbreaks in West Africa: case counts. Atlanta, GA: Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html. Accessed: November 11, 2015.
8. Ksiazek, T. G., P. E. Rollin, A. J. Williams, D. S. Bressler, M. L. Martin, R. Swanepoel, F. J. Burt, P. A. Leman, A. S. Khan, A. K. Rowe, et al. 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179(Suppl. 1): S177-S187.
9. Hunt, L., A. Gupta-Wright, V. Simms, F. Tamba, V. Knott, K. Tamba, S. Heisenberg-Mansaray, E. Tamba, A. Sheriff, S. Conteh, et al. 2015. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect. Dis. 15: 1292-1299.
10. Liddell, A. M., R. T. Davey, Jr., A. K. Mehta, J. B. Varkey, C. S. Kraft, G. K. Tseggay, O. Badidi, A. C. Faust, K. V. Brown, A. F. Suffredini, et al. 2015. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann. Intern. Med. 163: 81-90.
11. Qin, E., J. Bi, M. Zhao, Y. Wang, T. Guo, T. Yan, Z. Li, J. Sun, J. Zhang, S. Chen, et al. 2015. Clinical features of patients with Ebola virus disease in Sierra Leone. Clin. Infect. Dis. 61: 491-495.
12. Schieffelin, J. S., J. G. Shaffer, A. Goba, M. Gbakie, S. K. Gire, A. Colubri, R. S. Sealfon, L. Kanneh, A. Moigboi, M. Momoh, et al; WHO Clinical Response Team. 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N. Engl. J. Med. 371: 2092-2100.
13. Wong, K. K., C. L. Perdue, J. Malia, J. L. Kenney, S. Peng, J. K. Gwathney, and G. A. Raczniak; Monrovia Medical Unit. 2015. Supportive care of the first 2 Ebola virus disease patients at the Monrovia Medical Unit. Clin. Infect. Dis. 61: e47-e51.
14. Nanclares, C., J. Kapetshi, F. Lionetto, O. de la Rosa, J. J. Tamfun, M. Alia, G. Kobinger, and A. Bernasconi. 2016. Ebola virus disease, Democratic Republic of the Congo, 2014. Emerg. Infect. Dis. 22: 1579-1586.
15. Bah, E. I., M. C. Lamah, T. Fletcher, S. T. Jacob, D. M. Brett-Major, A. A. Sall, N. Shindo, W. A. Fischer, II, F. Lamontagne, S. M. Saliou, et al. 2015. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N. Engl. J. Med. 372: 40-47.
16. Crowe, S. J., M. J. Maenner, S. Kuah, B. R. Erickson, M. Coffee, B. Knust, J. Klena, J. Foday, D. Hertz, V. Hermans, et al. 2016. Prognostic indicators for Ebola patient survival. Emerg. Infect. Dis. 22: 217-223.
17. Qureshi, A. I., M. Chughtai, T. O. Loua, J. Pe Kolie, H. F. Camara, M. F. Ishfaq, C. T. N'Dour, and K. Beavogui. 2015. Study of Ebola virus disease survivors in Guinea. Clin. Infect. Dis. 61: 1035-1042.
18. Hereth-Hebert, E., M. O. Bah, J. F. Etard, M. S. Sow, S. Resnikoff, C. Fardeau, A. Toure, A. N. Ouendeno, I. C. Sagno, L. March, et al; Postebogui Study Group. 2017. Ocular complications in survivors of the Ebola outbreak in Guinea. Am. J. Ophthalmol. 175: 114-121.
19. Deen, G. F., B. Knust, N. Broutet, F. R. Sesay, P. Formenty, C. Ross, A. E. Thorson, T. A. Massaquoi, J. E. Marrinan, E. Ervin, et al. 2015. Ebola RNA persistence in semen of Ebola virus disease survivors - preliminary report. N. Engl. J. Med. 377: 1428-1437.
20. Rodriguez, L. L., A. De Roo, Y. Guimard, S. G. Trappier, A. Sanchez, D. Bressler, A. J. Williams, A. K. Rowe, J. Bertolli, A. S. Khan, et al. 1999. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. 179(Suppl. 1): S170-S176.
21. Varkey, J. B., J. G. Shantha, I. Crozier, C. S. Kraft, G. M. Lyon, A. K. Mehta, G. Kumar, J. R. Smith, M. H. Kainulainen, S. Whitmer, et al. 2015. Persistence of Ebola virus in ocular fluid during convalescence. N. Engl. J. Med. 372: 2423-2427.
22. Jacobs, M., A. Rodger, D. J. Bell, S. Bhagani, I. Cropley, A. Filipe, R. J. Gifford, S. Hopkins, J. Hughes, F. Jabeen, et al. 2016. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388: 498-503.
23. Baggi, F. M., A. Taybi, A. Kurth, M. Van Herp, A. Di Caro, R. Wölfel, S. Gunther, T. Decroo, H. Declerck, and S. Jonckheere. 2014. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. Euro Surveill. 19: 1-4.
24. Christie, A., G. J. Davies-Wayne, T. Cordier-Lassalle, D. J. Blackley, A. S. Laney, D. E. Williams, S. A. Shinde, M. Badio, T. Lo, S. E. Mate, et al; Centers for Disease Control and Prevention (CDC). 2015. Possible sexual transmission of Ebola virus - Liberia, 2015. [Published erratum appears in 2015 MMWR Morb. Mortal. Wkly. Rep. 64: 1180.] MMWR Morb. Mortal. Wkly. Rep. 64: 479-481.
25. Moreau, M., C. Spencer, J. G. Gozalbes, R. Colebunders, A. Lefevre, S. Gryseels, B. Borremans, S. Gunther, D. Becker, J. A. Bore, et al. 2015. Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. Euro Surveill. 20: 1-3.
26. Rowe, A. K., J. Bertolli, A. S. Khan, R. Mukunu, J. J. Muyembe-Tamfum, D. Bressler, A. J. Williams, C. J. Peters, L. Rodriguez, H. Feldmann, et al. 1999. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J. Infect. Dis. 179(Suppl. 1): S28-S35.
27. Derdeyn, C. A., J. M. Decker, F. Bibollet-Ruche, J. L. Mokili, M. Muldoon, S. A. Denham, M. L. Heil, F. Kasolo, R. Musonda, B. H. Hahn, et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022.
28. Wilker, P. R., J. M. Dinis, G. Starrett, M. Imai, M. Hatta, C. W. Nelson, D. H. O'Connor, A. L. Hughes, G. Neumann, Y. Kawaoka, and T. C. Friedrich. 2013. Selection on haemagglutinin imposes a bottleneck during mammalian transmission of reassortant H5N1 influenza viruses. Nat. Commun. 4: 2636.
29. Bull, R. A., F. Luciani, K. McElroy, S. Gaudieri, S. T. Pham, A. Chopra, B. Cameron, L. Maher, G. J. Dore, P. A. White, and A. R. Lloyd. 2011. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog. 7: e1002243.
30. Moya, A., E. C. Holmes, and F. González-Candelas. 2004. The population genetics and evolutionary epidemiology of RNA viruses. Nat. Rev. Microbiol. 2: 279-288.
31. Joseph, S. B., R. Swanstrom, A. D. Kashuba, and M. S. Cohen. 2015. Bottlenecks in HIV-1 transmission: insights from the study of founder viruses. Nat. Rev. Microbiol. 13: 414-425.
32. Holmes, E. C., G. Dudas, A. Rambaut, and K. G. Andersen. 2016. The evolution of Ebola virus: insights from the 2013-2016 epidemic. Nature 538: 193-200.
33. Dudas, G., L. M. Carvalho, T. Bedford, A. J. Tatem, G. Baele, N. R. Faria, D. J. Park, J. T. Ladner, A. Arias, D. Asogun, et al. 2017. Virus genomes reveal factors that spread and sustained the Ebola epidemic. Nature 544: 309-315.
34. Leroy, E. M., S. Baize, E. Mavoungou, and C. Apetrei. 2002. Sequence analysis of the GP, NP, VP40 and VP24 genes of Ebola virus isolated from deceased, surviving and asymptomatically infected individuals during the 1996 outbreak in Gabon: comparative studies and phylogenetic characterization. J. Gen. Virol. 83: 67-73.
35. Bray, M. 2001. The role of the type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82: 1365-1373.
36. Rasmussen, A. L., A. Okumura, M. T. Ferris, R. Green, F. Feldmann, S. M. Kelly, D. P. Scott, D. Safronetz, E. Haddock, R. LaCasse, et al. 2014. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science 346: 987-991.
37. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178: 651-661.
38. Mestas, J., and C. C. Hughes. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172: 2731-2738.
39. Xu, L., A. Sanchez, Z. Yang, S. R. Zaki, E. G. Nabel, S. T. Nichol, and G. J. Nabel. 1998. Immunization for Ebola virus infection. Nat. Med. 4: 37-42.
40. Rao, M., M. Bray, C. R. Alving, P. Jahrling, and G. R. Matyas. 2002. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J. Virol. 76: 9176-9185.
41. Qiu, X., L. Fernando, P. L. Melito, J. Audet, H. Feldmann, G. Kobinger, J. B. Alimonti, and S. M. Jones. 2012. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl. Trop. Dis. 6: e1575.
42. Geisbert, T. W., P. B. Jahrling, T. Larsen, K. J. Davis, and L. Hensley. 2003. Filovirus pathogenesis in nonhuman primates. Fort Detrick, MD: Army Medical Research Institute of Infectious Diseases. Available at: http://www.dtic.mil/dtic/tr/fulltext/u2/a421420.pdf.
43. Geisbert, T. W., L. E. Hensley, T. Larsen, H. A. Young, D. S. Reed, J. B. Geisbert, D. P. Scott, E. Kagan, P. B. Jahrling, and K. J. Davis. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163: 2347-2370.
44. Basler, C. F. 2015. Innate immune evasion by filoviruses. Virology 479-480: 122-130.
45. Messaoudi, I., G. K. Amarasinghe, and C. F. Basler. 2015. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13: 663-676.
46. Gupta, M., S. Mahanty, R. Ahmed, and P. E. Rollin. 2001. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology 284: 20-25.
47. Kash, J. C., K. A. Walters, J. Kindrachuk, D. Baxter, K. Scherler, K. B. Janosko, R. D. Adams, A. S. Herbert, R. M. James, S. W. Stonier, et al. 2017. Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease. Sci. Transl. Med. 9: eaai9321.
48. Villinger, F., P. E. Rollin, S. S. Brar, N. F. Chikkala, J. Winter, J. B. Sundstrom, S. R. Zaki, R. Swanepoel, A. A. Ansari, and C. J. Peters. 1999. Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J. Infect. Dis. 179 (Suppl. 1): S188-S191.
49. Liu, X., E. Speranza, C. Muñoz-Fontela, S. Haldenby, N. Y. Rickett, I. Garcia-Dorival, Y. Fang, Y. Hall, E. G. Zekeng, A. Ludtke, € et al. 2017. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol. 18: 4.
50. Baize, S., P. Marianneau, P. Loth, S. Reynard, A. Journeaux, M. Chevallier, N. Tordo, V. Deubel, and H. Contamin. 2009. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 83: 5890-5903.
51. Malleret, B., B. Manéglier, I. Karlsson, P. Lebon, M. Nascimbeni, L. Perié, P. Brochard, B. Delache, J. Calvo, T. Andrieu, et al. 2008. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 112: 4598-4608.
52. Jacquelin, B., V. Mayau, B. Targat, A. S. Liovat, D. Kunkel, G. Petitjean, M. A. Dillies, P. Roques, C. Butor, G. Silvestri, et al. 2009. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 119: 3544-3555.
53. Marzi, A., P. W. Hanley, E. Haddock, C. Martellaro, G. Kobinger, and H. Feldmann. 2016. Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus makona. J. Infect. Dis. 214 (Suppl. 3): S360-S366.
54. Misasi, J., and N. J. Sullivan. 2014. Camouflage and misdirection: the full-on assault of ebola virus disease. Cell 159: 477-486.
55. Channappanavar, R., A. R. Fehr, R. Vijay, M. Mack, J. Zhao, D. K. Meyerholz, and S. Perlman. 2016. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19: 181-193.
56. Sandler, N. G., S. E. Bosinger, J. D. Estes, R. T. Zhu, G. K. Tharp, E. Boritz, D. Levin, S. Wijeyesinghe, K. N. Makamdop, G. Q. del Prete, et al. 2014. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511: 601-605.
57. Wang, Y., M. Swiecki, M. Cella, G. Alber, R. D. Schreiber, S. Gilfillan, and M. Colonna. 2012. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 11: 631-642.
58. Swiecki, M., S. Gilfillan, W. Vermi, Y. Wang, and M. Colonna. 2010. Plasma-cytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8(+) T cell accrual. Immunity 33: 955-966.
59. Teijaro, J. R., C. Ng, A. M. Lee, B. M. Sullivan, K. C. Sheehan, M. Welch, R. D. Schreiber, J. C. de la Torre, and M. B. Oldstone. 2013. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340: 207-211.
60. Wilson, E. B., D. H. Yamada, H. Elsaesser, J. Herskovitz, J. Deng, G. Cheng, B. J. Aronow, C. L. Karp, and D. G. Brooks. 2013. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340: 202-207.
61. Bosio, C. M., M. J. Aman, C. Grogan, R. Hogan, G. Ruthel, D. Negley, M. Mohamadzadeh, S. Bavari, and A. Schmaljohn. 2003. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188: 1630-1638.
62. Mahanty, S., K. Hutchinson, S. Agarwal, M. McRae, P. E. Rollin, and B. Pulendran. 2003. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol. 170: 2797-2801.
63. Lubaki, N. M., P. Ilinykh, C. Pietzsch, B. Tigabu, A. N. Freiberg, R. A. Koup, and A. Bukreyev. 2013. The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J. Virol. 87: 7471-7485.
64. Hensley, L. E., H. A. Young, P. B. Jahrling, and T. W. Geisbert. 2002. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80: 169-179.
65. Leung, L. W., M. S. Park, O. Martinez, C. Valmas, C. B. López, and C. F. Basler. 2011. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol. Cell Biol. 89: 792-802.
66. Jahrling, P. B., T. W. Geisbert, J. B. Geisbert, J. R. Swearengen, M. Bray, N. K. Jaax, J. W. Huggins, J. W. LeDuc, and C. J. Peters. 1999. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J. Infect. Dis. 179(Suppl. 1): S224-S234.
67. Smith, L. M., L. E. Hensley, T. W. Geisbert, J. Johnson, A. Stossel, A. Honko, J. Y. Yen, J. Geisbert, J. Paragas, E. Fritz, et al. 2013. Interferon-b therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis. 208: 310-318.
68. Baize, S., E. M. Leroy, A. J. Georges, M. C. Georges-Courbot, M. Capron, I. Bedjabaga, J. Lansoud-Soukate, and E. Mavoungou. 2002. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol. 128: 163-168.
69. Ebihara, H., B. Rockx, A. Marzi, F. Feldmann, E. Haddock, D. Brining, R. A. LaCasse, D. Gardner, and H. Feldmann. 2011. Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J. Infect. Dis. 204(Suppl. 3): S991-S999.
70. Wauquier, N., P. Becquart, C. Padilla, S. Baize, and E. M. Leroy. 2010. Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis. 4: e837.
71. McElroy, A. K., J. R. Harmon, T. D. Flietstra, S. Campbell, A. K. Mehta, C. S. Kraft, M. G. Lyon, J. B. Varkey, B. S. Ribner, C. J. Kratochvil, et al. 2016. Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. Clin. Infect. Dis. 63: 460-467.
72. Ruibal, P., L. Oestereich, A. Ludtke, € B. Becker-Ziaja, D. M. Wozniak, R. Kerber, M. Korva, M. Cabeza-Cabrerizo, J. A. Bore, F. R. Koundouno, et al. 2016. Unique human immune signature of Ebola virus disease in Guinea. Nature 533: 100-104.
73. Hellman, J. 2015. Addressing the complications of Ebola and other viral hemorrhagic fever infections: using insights from bacterial and fungal sepsis. PLoS Pathog. 11: e1005088.
74. Ströher, U., E. West, H. Bugany, H. D. Klenk, H. J. Schnittler, and H. Feldmann. 2001. Infection and activation of monocytes by Marburg and Ebola viruses. J. Virol. 75: 11025-11033.
75. Kobasa, D., S. M. Jones, K. Shinya, J. C. Kash, J. Copps, H. Ebihara, Y. Hatta, J. H. Kim, P. Halfmann, M. Hatta, et al. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319-323.
76. Kobasa, D., A. Takada, K. Shinya, M. Hatta, P. Halfmann, S. Theriault, H. Suzuki, H. Nishimura, K. Mitamura, N. Sugaya, et al. 2004. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431: 703-707.
77. Fisher-Hoch, S. P., G. S. Platt, G. Lloyd, D. I. Simpson, G. H. Neild, and A. J. Barrett. 1983. Haematological and biochemical monitoring of Ebola infection in rhesus monkeys: implications for patient management. Lancet 2: 1055-1058.
78. Fisher-Hoch, S. P., G. S. Platt, G. H. Neild, T. Southee, A. Baskerville, R. T. Raymond, G. Lloyd, and D. I. Simpson. 1985. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J. Infect. Dis. 152: 887-894.
79. Mohamadzadeh, M., S. S. Coberley, G. G. Olinger, W. V. Kalina, G. Ruthel, C. L. Fuller, D. L. Swenson, W. D. Pratt, D. B. Kuhns, and A. L. Schmaljohn. 2006. Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by marburg and ebola viruses. J. Virol. 80: 7235-7244.
80. Reed, D. S., L. E. Hensley, J. B. Geisbert, P. B. Jahrling, and T. W. Geisbert. 2004. Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol. 17: 390-400.
81. Martin, M. P., Y. Qi, X. Gao, E. Yamada, J. N. Martin, F. Pereyra, S. Colombo, E. E. Brown, W. L. Shupert, J. Phair, et al. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39: 733-740.
82. Khakoo, S. I., C. L. Thio, M. P. Martin, C. R. Brooks, X. Gao, J. Astemborski, J. Cheng, J. J. Goedert, D. Vlahov, M. Hilgartner, et al. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305: 872-874.
83. Warfield, K. L., J. G. Perkins, D. L. Swenson, E. M. Deal, C. M. Bosio, M. J. Aman, W. M. Yokoyama, H. A. Young, and S. Bavari. 2004. Role of natural killer cells in innate protection against lethal ebola virus infection. J. Exp. Med. 200: 169-179.
84. Baize, S., E. M. Leroy, M. C. Georges-Courbot, M. Capron, J. Lansoud-Soukate, P. Debré, S. P. Fisher-Hoch, J. B. McCormick, and A. J. Georges. 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5: 423-426.
85. Sullivan, N. J., J. E. Martin, B. S. Graham, and G. J. Nabel. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. [Published erratum appears in 2009 Nat. Rev. Microbiol. 7: 684.] Nat. Rev. Microbiol. 7: 393-400.
86. Mupapa, K., M. Massamba, K. Kibadi, K. Kuvula, A. Bwaka, M. Kipasa, R. Colebunders, and J. J. Muyembe-Tamfum, International Scientific and Technical Committee. 1999. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J. Infect. Dis. 179(Suppl. 1): S18-S23.
87. McElroy, A. K., R. S. Akondy, C. W. Davis, A. H. Ellebedy, A. K. Mehta, C. S. Kraft, G. M. Lyon, B. S. Ribner, J. Varkey, J. Sidney, et al. 2015. Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. USA 112: 4719-4724.
88. Kraft, C. S., A. L. Hewlett, S. Koepsell, A. M. Winkler, C. J. Kratochvil, L. Larson, J. B. Varkey, A. K. Mehta, G. M. Lyon, III, R. J. Friedman-Moraco, et al; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. 2015. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 61: 496-502.
89. van Griensven, J., T. Edwards, X. de Lamballerie, M. G. Semple, P. Gallian, S. Baize, P. W. Horby, H. Raoul, N. Magassouba, A. Antierens, et al. 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374: 33-42.
90. Sahr, F., R. Ansumana, T. A. Massaquoi, B. R. Idriss, F. R. Sesay, J. M. Lamin, S. Baker, S. Nicol, B. Conton, W. Johnson, et al. 2017. Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. J. Infect. 74: 302-309.
91. Jahrling, P. B., J. B. Geisbert, J. R. Swearengen, T. Larsen, and T. W. Geisbert. 2007. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 196(Suppl. 2): S400-S403.
92. Jahrling, P. B., T. W. Geisbert, N. K. Jaax, M. A. Hanes, T. G. Ksiazek, and C. J. Peters. 1996. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic. Arch. Virol. Suppl. 11: 115-134.
93. Dye, J. M., A. S. Herbert, A. I. Kuehne, J. F. Barth, M. A. Muhammad, S. E. Zak, R. A. Ortiz, L. I. Prugar, and W. D. Pratt. 2012. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. USA 109: 5034-5039.
94. Sullivan, N. J., L. Hensley, C. Asiedu, T. W. Geisbert, D. Stanley, J. Johnson, A. Honko, G. Olinger, M. Bailey, J. B. Geisbert, et al. 2011. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17: 1128-1131.
95. Beniac, D. R., P. L. Melito, S. L. Devarennes, S. L. Hiebert, M. J. Rabb, L. L. Lamboo, S. M. Jones, and T. F. Booth. 2012. The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. PLoS One 7: e29608.
96. Alvarez, C. P., F. Lasala, J. Carrillo, O. Muñiz, A. L. Corbí, and R. Delgado. 2002. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J. Virol. 76: 6841-6844.
97. Kondratowicz, A. S., N. J. Lennemann, P. L. Sinn, R. A. Davey, C. L. Hunt, S. Moller-Tank, D. K. Meyerholz, P. Rennert, R. F. Mullins, M. Brindley, et al. 2011. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc. Natl. Acad. Sci. USA 108: 8426-8431.
98. Moller-Tank, S., A. S. Kondratowicz, R. A. Davey, P. D. Rennert, and W. Maury. 2013. Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. J. Virol. 87: 8327-8341.
99. Nanbo, A., M. Imai, S. Watanabe, T. Noda, K. Takahashi, G. Neumann, P. Halfmann, and Y. Kawaoka. 2010. Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog. 6: e1001121.
100. Saeed, M. F., A. A. Kolokoltsov, T. Albrecht, and R. A. Davey. 2010. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 6: e1001110.
101. Shimojima, M., A. Takada, H. Ebihara, G. Neumann, K. Fujioka, T. Irimura, S. Jones, H. Feldmann, and Y. Kawaoka. 2006. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J. Virol. 80: 10109-10116.
102. Aleksandrowicz, P., A. Marzi, N. Biedenkopf, N. Beimforde, S. Becker, T. Hoenen, H. Feldmann, and H. J. Schnittler. 2011. Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis. J. Infect. Dis. 204(Suppl. 3): S957-S967.
103. Misasi, J., M. S. Gilman, M. Kanekiyo, M. Gui, A. Cagigi, S. Mulangu, D. Corti, J. E. Ledgerwood, A. Lanzavecchia, J. Cunningham, et al. 2016. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351: 1343-1346.
104. Hood, C. L., J. Abraham, J. C. Boyington, K. Leung, P. D. Kwong, and G. J. Nabel. 2010. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunoge-nicity. J. Virol. 84: 2972-2982.
105. Chandran, K., N. J. Sullivan, U. Felbor, S. P. Whelan, and J. M. Cunningham. 2005. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308: 1643-1645.
106. Côté, M., J. Misasi, T. Ren, A. Bruchez, K. Lee, C. M. Filone, L. Hensley, Q. Li, D. Ory, K. Chandran, and J. Cunningham. 2011. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477: 344-348.
107. Carette, J. E., M. Raaben, A. C. Wong, A. S. Herbert, G. Obernosterer, N. Mulherkar, A. I. Kuehne, P. J. Kranzusch, A. M. Griffin, G. Ruthel, et al. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343.
108. Schornberg, K., S. Matsuyama, K. Kabsch, S. Delos, A. Bouton, and J. White. 2006. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80: 4174-4178.
109. Qiu, X., G. Wong, J. Audet, A. Bello, L. Fernando, J. B. Alimonti, H. Fausther-Bovendo, H. Wei, J. Aviles, E. Hiatt, et al. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514: 47-53.
110. Olinger, G. G., Jr., J. Pettitt, D. Kim, C. Working, O. Bohorov, B. Bratcher, E. Hiatt, S. D. Hume, A. K. Johnson, J. Morton, et al. 2012. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. USA 109: 18030-18035.
111. Qiu, X., J. Audet, G. Wong, S. Pillet, A. Bello, T. Cabral, J. E. Strong, F. Plummer, C. R. Corbett, J. B. Alimonti, and G. P. Kobinger. 2012. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4: 138ra81.
112. Corti, D., J. Misasi, S. Mulangu, D. A. Stanley, M. Kanekiyo, S. Wollen, A. Ploquin, N. A. Doria-Rose, R. P. Staupe, M. Bailey, et al. 2016. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351: 1339-1342.
113. PREVAIL II Writing Group; Multi-National PREVAIL II Study Team, R. T. Davey, Jr., L. Dodd, M. A. Proschan, J. Neaton, J. Neuhaus Nordwall, J. S. Koopmeiners, J. Beigel, J. Tierney, H. C. Lane, and A. S. Fauci, et al. 2016. A randomized, controlled trial of ZMapp for Ebola virus infection. N. Engl. J. Med. 375: 1448-1456.
114. Pettit, D. K., R. S. Rogers, K. Arthur, Y. Brodsky, R. H. Clark, C. Crowell, J. Ennis, A. Gillespie, R. Gillespie, B. Livingston, et al. 2016. CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody. MAbs 8: 347-357.
115. Murin, C. D., M. L. Fusco, Z. A. Bornholdt, X. Qiu, G. G. Olinger, L. Zeitlin, G. P. Kobinger, A. B. Ward, and E. O. Saphire. 2014. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci. USA 111: 17182-17187.
116. Qiu, X., J. Audet, M. Lv, S. He, G. Wong, H. Wei, L. Luo, L. Fernando, A. Kroeker, H. Fausther Bovendo, et al. 2016. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci. Transl. Med. 8: 329ra33.
117. Oswald, W. B., T. W. Geisbert, K. J. Davis, J. B. Geisbert, N. J. Sullivan, P. B. Jahrling, P. W. Parren, and D. R. Burton. 2007. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3: e9.
118. Marzi, A., R. Yoshida, H. Miyamoto, M. Ishijima, Y. Suzuki, M. Higuchi, Y. Matsuyama, M. Igarashi, E. Nakayama, M. Kuroda, et al. 2012. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 7: e36192.
119. Gunn, B. M., and G. Alter. 2016. Modulating antibody functionality in infectious disease and vaccination. Trends Mol. Med. 22: 969-982.
120. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
121. DiLillo, D. J., G. S. Tan, P. Palese, and J. V. Ravetch. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgR interactions for protection against influenza virus in vivo. Nat. Med. 20: 143-151.
122. Liu, Q., C. Fan, Q. Li, S. Zhou, W. Huang, L. Wang, C. Sun, M. Wang, X. Wu, J. Ma, et al. 2017. Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection. Sci. Rep. 7: 45552.
123. Halstead, S. B. 1970. Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J. Biol. Med. 42: 350-362.
124. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shvedoff, and C. E. Stewart. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89: 405-421.
125. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89: 422-434.
126. Takada, A., and Y. Kawaoka. 2003. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13: 387-398.
127. Takada, A., H. Ebihara, H. Feldmann, T. W. Geisbert, and Y. Kawaoka. 2007. Epitopes required for antibody-dependent enhancement of Ebola virus infection. J. Infect. Dis. 196(Suppl. 2): S347-S356.
128. Takada, A., H. Feldmann, T. G. Ksiazek, and Y. Kawaoka. 2003. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77: 7539-7544.
129. Agrati, C., C. Castilletti, R. Casetti, A. Sacchi, L. Falasca, F. Turchi, N. Tumino, V. Bordoni, E. Cimini, D. Viola, et al. 2016. Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection. Cell Death Dis. 7: e2164.
130. Miller, J. D., R. G. van der Most, R. S. Akondy, J. T. Glidewell, S. Albott, D. Masopust, K. Murali-Krishna, P. L. Mahar, S. Edupuganti, S. Lalor, et al. 2008. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
131. Lindgren, T., C. Ahlm, N. Mohamed, M. Evander, H. G. Ljunggren, and N. K. Björkström. 2011. Longitudinal analysis of the human T cell response during acute hantavirus infection. J. Virol. 85: 10252-10260.
132. Sanchez, A., M. Lukwiya, D. Bausch, S. Mahanty, A. J. Sanchez, K. D. Wagoner, and P. E. Rollin. 2004. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J. Virol. 78: 10370-10377.
133. Stanley, D. A., A. N. Honko, C. Asiedu, J. C. Trefry, A. W. Lau-Kilby, J. C. Johnson, L. Hensley, V. Ammendola, A. Abbate, F. Grazioli, et al. 2014. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20: 1126-1129.
134. Zhou, Y., and N. J. Sullivan. 2015. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Curr. Opin. Immunol. 35: 131-136.
135. Hensley, L. E., S. Mulangu, C. Asiedu, J. Johnson, A. N. Honko, D. Stanley, G. Fabozzi, S. T. Nichol, T. G. Ksiazek, P. E. Rollin, et al. 2010. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog. 6: e1000904.
136. Marzi, A., F. Engelmann, F. Feldmann, K. Haberthur, W. L. Shupert, D. Brining, D. P. Scott, T. W. Geisbert, Y. Kawaoka, M. G. Katze, et al. 2013. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl. Acad. Sci. USA 110: 1893-1898.
137. Fukazawa, Y., R. Lum, A. A. Okoye, H. Park, K. Matsuda, J. Y. Bae, S. I. Hagen, R. Shoemaker, C. Deleage, C. Lucero, et al. 2015. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21: 132-139.
138. Schmitz, J. E., M. A. Simon, M. J. Kuroda, M. A. Lifton, M. W. Ollert, C. W. Vogel, P. Racz, K. Tenner-Racz, B. J. Scallon, M. Dalesandro, et al. 1999. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154: 1923-1932.
139. Van Rompay, K. K., Z. Hunter, K. Jayashankar, J. Peabody, D. Montefiori, C. C. LaBranche, B. F. Keele, K. Jensen, K. Abel, and B. Chackerian. 2014. A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J. Virol. 88: 2011-2024.
140. Plotkin, S. A. 2013. Complex correlates of protection after vaccination. Clin. Infect. Dis. 56: 1458-1465.
141. Chughtai, A. A., M. Barnes, and C. R. Macintyre. 2016. Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. Epidemiol. Infect. 144: 1652-1660.
142. Dahlke, C., S. Lunemann, R. Kasonta, B. Kreuels, S. Schmiedel, M. L. Ly, S. K. Fehling, T. Strecker, S. Becker, M. Altfeld, et al. 2017. Comprehensive characterization of cellular immune responses following Ebola virus infection. J. Infect. Dis. 215: 287-292.
143. Lanini, S., G. Portella, F. Vairo, G. P. Kobinger, A. Pesenti, M. Langer, S. Kabia, G. Brogiato, J. Amone, C. Castilletti, et al; INMI-EMERGENCY EBOV Sierra Leone Study Group. 2015. Blood kinetics of Ebola virus in survivors and nonsurvivors. J. Clin. Invest. 125: 4692-4698.
144. Bharat, T. A., T. Noda, J. D. Riches, V. Kraehling, L. Kolesnikova, S. Becker, Y. Kawaoka, and J. A. Briggs. 2012. Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proc. Natl. Acad. Sci. USA 109: 4275-4280.
145. Hartlieb, B., J. Modrof, E. Muhlberger, H. D. Klenk, and S. Becker. 2003. Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J. Biol. Chem. 278: 41830-41836.
146. Hartlieb, B., T. Muziol, W. Weissenhorn, and S. Becker. 2007. Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association. Proc. Natl. Acad. Sci. USA 104: 624-629.
147. Modrof, J., S. Becker, and E. Muhlberger. € 2003. Ebola virus transcription activator VP30 is a zinc-binding protein. J. Virol. 77: 3334-3338.
148. Muhlberger, € E., M. Weik, V. E. Volchkov, H. D. Klenk, and S. Becker. 1999. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73: 2333-2342.
149. Sanchez, A., and M. P. Kiley. 1987. Identification and analysis of Ebola virus messenger RNA. Virology 157: 414-420.
150. Sanchez, A., M. P. Kiley, B. P. Holloway, and D. D. Auperin. 1993. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 29: 215-240.
151. Sanchez, A., S. G. Trappier, B. W. Mahy, C. J. Peters, and S. T. Nichol. 1996. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 93: 3602-3607.
152. Biedenkopf, N., B. Hartlieb, T. Hoenen, and S. Becker. 2013. Phosphorylation of Ebola virus VP30 influences the composition of the viral nucleocapsid complex: impact on viral transcription and replication. J. Biol. Chem. 288: 11165-11174.
153. Martinez, M. J., V. A. Volchkova, H. Raoul, N. Alazard-Dany, O. Reynard, and V. E. Volchkov. 2011. Role of VP30 phosphorylation in the Ebola virus replication cycle. J. Infect. Dis. 204(Suppl. 3): S934-S940.
154. Stahelin, R. V. 2014. Membrane binding and bending in Ebola VP40 assembly and egress. Front. Microbiol. 5: 300.